Literature DB >> 23742019

Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.

Joshua P Fessel1, Charles R Flynn, Linda J Robinson, Niki L Penner, Santhi Gladson, Christie J Kang, David H Wasserman, Anna R Hemnes, James D West.   

Abstract

Pulmonary arterial hypertension (PAH) has been associated with a number of different but interrelated pathogenic mechanisms. Metabolic and oxidative stresses have been shown to play important pathogenic roles in a variety of model systems. However, many of these relationships remain at the level of association. We sought to establish a direct role for metabolic stress and oxidant injury in the pathogenesis of PAH. Mice that universally express a disease-causing mutation in bone morphogenic protein receptor 2 (Bmpr2) were exposed to room air or to brief daily hyperoxia (95% oxygen for 3 h) for 6 weeks, and were compared with wild-type animals undergoing identical exposures. In both murine tissues and cultured endothelial cells, the expression of mutant Bmpr2 was sufficient to cause oxidant injury that was particularly pronounced in mitochondrial membranes. With the enhancement of mitochondrial generation of reactive oxygen species by hyperoxia, oxidant injury was substantially enhanced in mitochondrial membranes, even in tissues distant from the lung. Hyperoxia, despite its vasodilatory actions in the pulmonary circulation, significantly worsened the PAH phenotype (elevated right ventricular systolic pressure, decreased cardiac output, and increased pulmonary vascular occlusion) in Bmpr2 mutant animals. These experiments demonstrate that oxidant injury and metabolic stress contribute directly to disease development, and provide further evidence for PAH as a systemic disease with life-limiting cardiopulmonary manifestations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23742019      PMCID: PMC3931097          DOI: 10.1165/rcmb.2012-0463OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  48 in total

1.  Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean.

Authors:  J C Clapham; J R Arch; H Chapman; A Haynes; C Lister; G B Moore; V Piercy; S A Carter; I Lehner; S A Smith; L J Beeley; R J Godden; N Herrity; M Skehel; K K Changani; P D Hockings; D G Reid; S M Squires; J Hatcher; B Trail; J Latcham; S Rastan; A J Harper; S Cadenas; J A Buckingham; M D Brand; A Abuin
Journal:  Nature       Date:  2000-07-27       Impact factor: 49.962

Review 2.  Uncoupling metabolism and coupling leptin to cardiovascular disease.

Authors:  Allyn L Mark; William I Sivitz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-06-01       Impact factor: 8.311

3.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

4.  Changes in pulmonary expression of hexokinase and glucose transporter mRNAs in rats adapted to hyperoxia.

Authors:  C B Allen; X L Guo; C W White
Journal:  Am J Physiol       Date:  1998-03

5.  Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels.

Authors:  Evangelos D Michelakis; M Sean McMurtry; Xi-Chen Wu; Jason R B Dyck; Rohit Moudgil; Teresa A Hopkins; Gary D Lopaschuk; Lakshmi Puttagunta; Ross Waite; Stephen L Archer
Journal:  Circulation       Date:  2002-01-15       Impact factor: 29.690

6.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

7.  Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension.

Authors:  Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

Review 8.  Primary pulmonary hypertension.

Authors:  James R Runo; James E Loyd
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

9.  Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats.

Authors:  Fumihiko Kamezaki; Hiromi Tasaki; Kazuhito Yamashita; Masato Tsutsui; Shinichiro Koide; Sei Nakata; Akihide Tanimoto; Masahiro Okazaki; Yasuyuki Sasaguri; Tetsuo Adachi; Yutaka Otsuji
Journal:  Am J Respir Crit Care Med       Date:  2007-10-25       Impact factor: 21.405

10.  Oxidative injury is a common consequence of BMPR2 mutations.

Authors:  Kirk L Lane; Megha Talati; Eric Austin; Anna R Hemnes; Jennifer A Johnson; Joshua P Fessel; Tom Blackwell; Ray L Mernaugh; Linda Robinson; Candice Fike; L Jackson Roberts; James West
Journal:  Pulm Circ       Date:  2011       Impact factor: 3.017

View more
  20 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series).

Authors:  Joshua P Fessel; James D West
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

3.  Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia.

Authors:  Maria Haslip; Iva Dostanic; Yan Huang; Yi Zhang; Kerry S Russell; Michael J Jurczak; Praveen Mannam; Frank Giordano; Serpil C Erzurum; Patty J Lee
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-26       Impact factor: 8.311

4.  Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.

Authors:  Xinping Chen; Megha Talati; Joshua P Fessel; Anna R Hemnes; Santhi Gladson; Jaketa French; Sheila Shay; Aaron Trammell; John A Phillips; Rizwan Hamid; Joy D Cogan; Elliott P Dawson; Kristie E Womble; Lora K Hedges; Elizabeth G Martinez; Lisa A Wheeler; James E Loyd; Susan J Majka; James West; Eric D Austin
Journal:  Circulation       Date:  2015-10-20       Impact factor: 29.690

5.  Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.

Authors:  Andrew J Bryant; Linda J Robinson; Christy S Moore; Thomas R Blackwell; Santhi Gladson; Niki L Penner; Ankita Burman; Lucas J McClellan; Vasiliy V Polosukhin; Harikrishna Tanjore; Melinda E McConaha; Linda A Gleaves; Megha A Talati; Anna R Hemnes; Joshua P Fessel; William E Lawson; Timothy S Blackwell; James D West
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

6.  BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.

Authors:  Isabel Diebold; Jan K Hennigs; Kazuya Miyagawa; Caiyun G Li; Nils P Nickel; Mark Kaschwich; Aiqin Cao; Lingli Wang; Sushma Reddy; Pin-I Chen; Kiichi Nakahira; Miguel A Alejandre Alcazar; Rachel K Hopper; Lijuan Ji; Brian J Feldman; Marlene Rabinovitch
Journal:  Cell Metab       Date:  2015-04-07       Impact factor: 27.287

7.  Mitochondrial dysfunction in the APP/PSEN1 mouse model of Alzheimer's disease and a novel protective role for ascorbate.

Authors:  Shilpy Dixit; Joshua P Fessel; Fiona E Harrison
Journal:  Free Radic Biol Med       Date:  2017-08-31       Impact factor: 7.376

8.  EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.

Authors:  Mélanie Eyries; David Montani; Barbara Girerd; Claire Perret; Anne Leroy; Christine Lonjou; Nadjim Chelghoum; Florence Coulet; Damien Bonnet; Peter Dorfmüller; Elie Fadel; Olivier Sitbon; Gérald Simonneau; David-Alexandre Tregouët; Marc Humbert; Florent Soubrier
Journal:  Nat Genet       Date:  2013-12-01       Impact factor: 38.330

9.  NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Authors:  Andriy O Samokhin; Thomas Stephens; Bradley M Wertheim; Rui-Sheng Wang; Sara O Vargas; Lai-Ming Yung; Minwei Cao; Marcel Brown; Elena Arons; Paul B Dieffenbach; Jason G Fewell; Majed Matar; Frederick P Bowman; Kathleen J Haley; George A Alba; Stefano M Marino; Rahul Kumar; Ivan O Rosas; Aaron B Waxman; William M Oldham; Dinesh Khanna; Brian B Graham; Sachiko Seo; Vadim N Gladyshev; Paul B Yu; Laura E Fredenburgh; Joseph Loscalzo; Jane A Leopold; Bradley A Maron
Journal:  Sci Transl Med       Date:  2018-06-13       Impact factor: 17.956

Review 10.  Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.

Authors:  Jeffrey D Marshall; Isabel Bazan; Yi Zhang; Wassim H Fares; Patty J Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-18       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.